Report: Bioprocessing trends 2018-2023

By Flora Southey contact

- Last updated on GMT

(Image: Getty/denizbayram)
(Image: Getty/denizbayram)

Related tags: CAR-T, Continuous manufacturing

Increased cell and gene therapy production and reduced development timelines are listed among bioprocessing trends predicted over the next five years, says consultant.

According to Mike Ultee of Ulteemit Bioconsulting, the bioprocessing industry should prepare for a number of growing trends in the development and manufacture of biologics. Among the predictions, cited in the CPhI Worldwide Annual Report​, are improved productivity of fusion proteins and enzymes, and the rise of continuous bioprocessing.

Chimeric antigen receptor (CAR) T-cell therapy pipelines will continue to advance towards commercialisation, said Ultee.

“In five years’ time, we will have been through a golden period, with game-changing improvements made in upstream, downstream and continuous bioprocessing.

“The market will by then also boast much greater numbers of biosimilars and new applications for cell and gene therapies. The industry is collectively maturing extremely quickly from big pharma and biosimilars to contract development and manufacturing organisations (CDMOs),” ​he added.

Related products

show more

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Downstream Purification of Large Biomolecules

Downstream Purification of Large Biomolecules

Bio-Rad Laboratories | 17-Sep-2018 | Research Study

Our newest strong anion exchange resin provides both high binding capacity and
high recovery, even at high flow rates. A rigid bead complete with...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us


View more